Sophie JEANNIN
CMO NorthSea Therapeutics
Dr. Sophie Jeannin Megnien is an accomplished medical executive with a distinguished career leading clinical development programs in hepatology and metabolic diseases. As Chief Medical Officer at Northsea Therapeutics, she oversees the company’s clinical strategy for developing innovative treatments targeting NASH and related metabolic disorders. With her strong therapeutic expertise and operational leadership, she guides programs from preclinical stages through clinical development.
Prior to joining Northsea, Dr. Jeannin Megnien served as Chief Medical Officer at GENFIT Corp, where she played a pivotal role in advancing the company’s pipeline of liver disease therapeutics. Her experience also includes serving as Chief Medical Officer at Summit Clinical Research, where she led clinical trial execution across multiple therapeutic areas. Earlier in her career, she applied her strategic expertise as Managing Consultant at SME Consulting, advising biotech companies on development and operational strategies.
Trained as a physician, Dr. Jeannin Megnien brings a patient-centric approach to drug development, combining scientific rigor with strategic vision.
Seminars
Join this interactive roundtable to reshape how we measure and reward innovation in obesity therapeutics through cardiometabolic endpoints. As the field moves beyond weight loss alone, this session will bring together regulators, payers, clinicians, and patient advocates to align on new success metrics that reflect the full value of obesity treatments.
- Standardising evidence beyond BMI by aligning regulators and payers on multi-organ cardiometabolic benefits such as imaging data and body composition metrics as critical endpoints for approval and reimbursement
- Balancing clinical and patient priorities through trial designs that capture both hard outcomes like cardiovascular risk reduction and quality-of-life improvements in mobility and daily functioning
- Demonstrating compelling value to payers by modelling long-term economic benefits, including cost savings from comorbidity improvement in conditions like NAFLD and metabolic syndrome
- Exploring how RWE and comparator strategies can address fragmented EU HTA expectations, as well as what post-launch validation data payers are demanding
- Addressing co-morbidities in obese patients
- Evaluating Icosabutate: a liver targeted, modified long chain fatty acid to improve glycaemic control, hepatic inflammation and fibrosis in MASH patients
- Identifying synergy for potential combination therapy with icosabutate and GLP-1 agonists
